Magnus Lindberg

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow et al. · Nephrology Dialysis Transplantation · 2019 · 216 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin

John G.F. Cleland, John J.V. McMurray, John Kjekshus et al. · Journal of the American College of Cardiology · 2009 · 204 citations

Medicine, Cardiology, Pharmacology +9

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

David C. Wheeler, Bergur V. Stefánsson, Oleksandr Bilchenko et al. · Nephrology Dialysis Transplantation · 2020 · 190 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

John J.V. McMurray, John Kjekshus, Lars Gullestad et al. · Circulation · 2009 · 161 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16